Gyre Therapeutics (GYRE) reported Q4 breakeven late Monday, compared with a net loss of $1.39 per diluted share a year earlier.
One analyst polled by FactSet expected earnings of $0.04 per share.
Revenue for the quarter ended Dec. 31 was $27.9 million, up from $27.1 million a year earlier.
One analyst surveyed by FactSet expected $23.5 million.
The company said it expects 2025 revenue between $118 million and $128 million.
One analyst polled by FactSet expects $135.7 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。